Additional Resources

Additional Resources

  1. Centers for Disease Control and Prevention. Healthcare Professionals. Available: https://www.cdc.gov/asthma/healthcare.html#guidelines
  2. National Jewish Health. https://www.nationaljewish.org/conditions/asthma
  3. National Asthma Education and Prevention Program (NAEPP). Available: https://www.nhlbi.nih.gov/science/national-asthma-education-and-prevention-program-naepp
  4. American College of Chest Physicians. http://www.chestnet.org/
  5. Abonia JP, Putnam PE. Mepolizumab in eosinophilic disorders. Expert Rev Clin Immunol. 2011 July: 7(4):411-417. doi:10.1586/eci.11.27
  6. Accordini S, Cappa V, Braggion M, et al. The impact of diagnosed and undiagnosed current asthma in the general adult population. Int Arch Allergy Immunol. 2011;155(4):403-11.
  7. Apter AJ, Wan F, Reisine S, et al. The association of health literacy with adherence and outcomes in moderate-severe asthma. J Allergy Clin Immunol. 2013;132(2):321-7.
  8. AstraZeneca provides an update on tralokinumab phase III programme in severe, uncontrolled asthma. Available at: https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-provides-update-ontralokinumab-phase-iii-programme-in-severe-uncontrolled-asthma-01112017.html. Accessed April 1, 2018.
  9. Bachert C, Mannent L, Naclerio RM et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis A Randomized Clinical Trial. 2016. JAMA; 315(5):469-479
  10. Badiola C, Badiella L, Plaza V, et al. Women, patients with severe asthma, and patients attended by primary care physicians, are at higher risk of suffering from poorly controlled asthma. Prim Care Respir J. 2009;18(4):294-9.
  11. Bel EH, Wenzel SE, Thompson PJ, et al. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. N Eng J Med. 2014: 371:1189-1197. doi:10.1056/NEJMoa/40329/
  12. Bisaccioni C, VivoloAun M, Cajuela E, et al. Comorbidities in Severe Asthma: Frequency of Rhinitis, Nasal Polyposis, GERD, Vocal Cord Dysfunction and Bronchiectasis. Clinics. 2009; 64(8):769-73
  13. Bleecker ER, FitzGerald M, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with highdosage inhaled corticosteroids and long acting β2 agonists (SIROCCO): a randomised, multicenter, placebo-controlled phase 3 trial. The Lancet. Vol 388, No 10056, p2115-2127, 29 Oct 2016. doi:10.1016/S0140-6736(16)31324-1
  14. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323: 1033–1039. Bjemer L, Lemiere C, et al. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest. 2016; 150(4):789-798. doi: 10.1016/j.chest.2016.03.032
  15. Brusselle G, McElhattan J, Canvin J, Buhl R. Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3 placebo (PBO)-controlled study. European Respiratory Journal. 2016, 48: PA4107; doi: 10.1183/13993003.
  16. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015.
  17. Chung KF, et al. International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma. Eur Respir J 2014; 43:343-373. doi:10.1183/09031936.00202013 Chung FK. Dupilumab: a potential new treatment for severe asthma. The Lancet. Vol 388, No 10039, p3-4. July 2016. doi:10.1016/50140-6736(16)30311-7
  18. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-73. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 Study of Reslizumab in Patients with Poorly Controlled Asthma. CHEST 2016;150(4):799-810 ClinicalTrials.gov. A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Uncontrolled Asthma (STRATOS1). ClinicalTrials.gov Identifier: NCT02161757
  19. Deykin A, Lazarus SC, Fahy JV, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol. 2005;115: 720-727. Diette GB, Rand C. The contributing role of health-care communication to health disparities for minority patients with asthma. Chest. 2007;132(5 Suppl):802S-9S.
  20. FitzGerald JM, Bleeker E et al. Benralizumab, an anti-interleukin-5 α monoclonal antibody as add on treatment for patient with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Vol 388, No 10056, p2128-2141. 29 Oct 2016. doi:10.1016/S0140-6736(16)31322-8
  21. Fox Huffaker M et al. Pediatric Asthma: Guidelines-Based Care. Omalizumab and other Potential Biologic Agents. Immnol Allergy Clin North Am. 2015 February; 35(1):129-144. doi: 10.1016/j.iac.2014.09.005
  22. Flood-Page P, Swenson C, et al. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma. American Journal of Respiratory and Critical Care Medicine. Vol 176, No 11 (2007), pp 1062-1071. doi:10.116/rccm.200701-085oc
  23. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008 Mar;8(3):205-217. doi:10.1038/nri2273.
  24. Hanania NA et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug:70(8):748-56. doi: 10.1136/thoraxjnl-2014-206719
  25. Hanania N, Korenblat P, Chapman KR, et al. Efficacy and Safety of Lebrikizumab in Patients with Uncontrolled Asthma (LAVOLTA I and LAVOLTA II): replicate phase 3 randomized, double-blind, placebo-controlled trials. The Lancet. Vol 4., No. 10., p781-796, Oct 2016. doi: 10.1016/S2213-2600(16)30265-X
  26. Jarjour NN, Erzurum SC, Bleecker E, et al. Severe asthma. Lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med. 2012;185: 356-362.
  27. Johansson MW. Serum periostin is associated with type-2 immunity in severe asthma. J Allergy Clin Immunol. Vol 137, No 6. doi:10.1016/j.jaci.2015.12.1346
  28. Juniper EF, Chauhan A, Neville E, et al. Clinicians tend to overestimate improvements in asthma control: an unexpected observation. Prim Care Respir J. 2004;13(4):181-4.
  29. Lai T, Shaobin W, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled asthma: a systemic review and meta-analysis. Scientific Reports. Article number: 8191 (2015) doi:10.1038/srep08191
  30. Laster N, Holsey CN, Shendell DG, et al. Barriers to asthma management among urban families: caregiver and child perspectives. J Asthma. 2009;46(7):731-9. McMahon AW. Et al. Age and Risks of FDA-Approved Long -Acting β2Adrenergic Agonists. Pediatrics. Nov 2011, 128(5)e1154; doi: 10.1542/peds.2010-1720
  31. Menzella F, Lusuardi M, Galeone C, Facciolongo N, Zucchi L. The clinical profile of benralizumab in the management of severe eosinophilic asthma. Ther Adv Respir Dis. 2016. Vol 10(6)534-548. Doi: 10.1177/1753465816667659 Moore WC, Peters SP. Severe asthma: An overview. Journal of Allergy and Clinical Immunology. 2006. Vol 117 Iss 3 pp487494
  32. Moore WC, Bleeker ER, Curran-Evereh D, et al. Characterization of severe asthma phenotypes by the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Journal of Allergy and Clinical Immunology. 2007. Vol 119 Iss 2 pp 405-413
  33. Moore WC, Meyers D, Wenzel S, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Amer J Respir Crit Care Med. 2010; 181: 315-323.
  34. National Heart, Lung, and Blood Institute (NHLBI). Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma – Summary Report 2007. Available at: https://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf.
  35. Nissim Ben Efraim AH, Levi-Schaffer F. Tissue remodeling and angiogenesis in asthma: the role of the eosinophil. Ther Adv Respir Dis. 2008;2: 163–171.
  36. National Asthma Education and Prevention Program, Expert panel report 3guidelines for diagnosis and management of asthma. NIH publication 08-4051. 2007: Bethesda, National Institutes of Health. Navaratnam P, Jayawant SS, Pedersen CA, et al. Physician adherence to the national asthma prescribing guidelines: evidence from national outpatient survey data in the United States. Ann Allergy Asthma Immunol. 2008;100(3):216-21.
  37. Normansell R et al. Omalizumab for asthma in adults and children. Cochrane Database of Systematic Reviews. 2014, Issue 1. Art. No:.CD003559. doi: 10.1002/14651858.CD003559.pub4 NOVELTY Study. ATLAS ID: 1,023,362,011. Prepared 12/16 available at: aznovelty.project.com site visited: 3/17
  38. Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33: 14-20.
  39. O’Byrne PM, Pedersen S, Schatz M, et al. The poorly explored impact of uncontrolled asthma. Chest. 2013;143(2):511-23.
  40. Ortega H, Yancey SW, Keene ON, et al. Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2018; Ortega HG, Liu MC, et al. Treatment in Patients with Severe Eosinophilic Asthma. N Eng J Med. 2014:371:1198-1207. doi:10.1056/NEJMoa1403290
  41. Payne DN, Rogers AV, Adelroth E, et al. Early thickening of the reticular basement membrane in children with difficult asthma. Am J Resp Crit Care Med. 2003;167: 78-82. Pelaia G, et al. Update on optimal use of omalizumab in management of asthma. Journal of Asthma and Allergy. 2011:4.4959. doi:10.2147/JAA.514520
  42. Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment. Respiratory Medicine. 2006: 100, 1139-1151. doi:10.1016/j.med.2006.03.031
  43. Renaud L, Laurie C, et al. The Relationship between Airway Inflammation and Asthma Severity. Amer J Respiratory Crit Care Med. Vol 161, No 1(2000), pp 9-16. doi:10.1164/ajrccm.161.1.9802048
  44. Russell R, Brightling CE. Anti-IL-5 for Severe Asthma. Chest. Volume 150, Issue 4, October 2016, pages 766-768. doi: 10.1016/j.chest.2016.06.013
  45. Simpson JL, Scott R, Boyle MJ, et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11: 54-61. Sin DD, Tu JV. Underuse of inhaled steroid therapy in elderly patients with asthma. Chest. 2001;119(3):720-5.
  46. Siroux V, Basagana X, Boudier A, et al. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J. 2011; 38: 310-317.
  47. Sokol KC, Sharma G, Lin YL, et al. Choosing wisely: adherence by physicians to recommended use of spirometry in the diagnosis and management of adult asthma. Am J Med. 2015;128(5):502-8.
  48. Tan LD, Bratt JM, Godor D, Louie S, Kenyon NJ. Benralizumab: a unique IL-5 inhibitor for severe asthma. Journal of Asthma and Allergy. 2016:9 71-78. doi:10.2147/JAA.S78049
  49. Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. The Lancet. 2016. Vol 387, Iss 10013, pp 40-52
  50. Tindemans I, Serafini N, Di Santo J, Hendriks R. GATA-3 function in innate and adaptive immunity. Immunity. 2014; 41: 191206.
  51. Vatrella A, Fabozzi I, Calabrese C, et al. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014; 7: 123-130.
  52. Walsh GM. An Update on Biologic-based Therapy in Asthma. Immunotherapy. 2013;5(11):1255-1264
  53. Walsh GM. Antagonism of eosinophil accumulation in asthma. Recent Pat Inflamm Allergy Drug Discov. 2010;4:210–213.
  54. Wechsler ME. Getting control of uncontrolled asthma. Am J Med. 2014;127(11):1049-59. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high dose inhaled corticosteroids plus a long acting β2 agonist: a randomised double-blind, placebo controlled pivotal phase 2b dose-ranging trial. The Lancet. Vol 388, No 10039, p31-44, July 2016. doi:10.1016/S01406736(16)30307-5
  55. Woodruff PG, Modrek B, Choy DF, et al. T-helper type2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009; 180: 388-395.